Jianchang Hu1, Cai Li1, Shiying Wang1, Ting Li1, Heping Zhang2. 1. Department of Biostatistics, Yale University, 300 George Street, Ste 523, New Haven, CT, 06511, USA. 2. Department of Biostatistics, Yale University, 300 George Street, Ste 523, New Haven, CT, 06511, USA. heping.zhang@yale.edu.
Abstract
BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly heterogeneous. Studies have reported that males and some ethnic groups are at increased risk of death from COVID-19, which implies that individual risk of death might be influenced by host genetic factors. METHODS: In this project, we consider the mortality as the trait of interest and perform a genome-wide association study (GWAS) of data for 1778 infected cases (445 deaths, 25.03%) distributed by the UK Biobank. Traditional GWAS fails to identify any genome-wide significant genetic variants from this dataset. To enhance the power of GWAS and account for possible multi-loci interactions, we adopt the concept of super variant for the detection of genetic factors. A discovery-validation procedure is used for verifying the potential associations. RESULTS: We find 8 super variants that are consistently identified across multiple replications as susceptibility loci for COVID-19 mortality. The identified risk factors on chromosomes 2, 6, 7, 8, 10, 16, and 17 contain genetic variants and genes related to cilia dysfunctions (DNAH7 and CLUAP1), cardiovascular diseases (DES and SPEG), thromboembolic disease (STXBP5), mitochondrial dysfunctions (TOMM7), and innate immune system (WSB1). It is noteworthy that DNAH7 has been reported recently as the most downregulated gene after infecting human bronchial epithelial cells with SARS-CoV-2. CONCLUSIONS: Eight genetic variants are identified to significantly increase the risk of COVID-19 mortality among the patients with white British ancestry. These findings may provide timely clues and potential directions for better understanding the molecular pathogenesis of COVID-19 and the genetic basis of heterogeneous susceptibility, with potential impact on new therapeutic options.
BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly heterogeneous. Studies have reported that males and some ethnic groups are at increased risk of death from COVID-19, which implies that individual risk of death might be influenced by host genetic factors. METHODS: In this project, we consider the mortality as the trait of interest and perform a genome-wide association study (GWAS) of data for 1778 infected cases (445 deaths, 25.03%) distributed by the UK Biobank. Traditional GWAS fails to identify any genome-wide significant genetic variants from this dataset. To enhance the power of GWAS and account for possible multi-loci interactions, we adopt the concept of super variant for the detection of genetic factors. A discovery-validation procedure is used for verifying the potential associations. RESULTS: We find 8 super variants that are consistently identified across multiple replications as susceptibility loci for COVID-19mortality. The identified risk factors on chromosomes 2, 6, 7, 8, 10, 16, and 17 contain genetic variants and genes related to cilia dysfunctions (DNAH7 and CLUAP1), cardiovascular diseases (DES and SPEG), thromboembolic disease (STXBP5), mitochondrial dysfunctions (TOMM7), and innate immune system (WSB1). It is noteworthy that DNAH7 has been reported recently as the most downregulated gene after infecting human bronchial epithelial cells with SARS-CoV-2. CONCLUSIONS: Eight genetic variants are identified to significantly increase the risk of COVID-19mortality among the patients with white British ancestry. These findings may provide timely clues and potential directions for better understanding the molecular pathogenesis of COVID-19 and the genetic basis of heterogeneous susceptibility, with potential impact on new therapeutic options.
Entities:
Keywords:
COVID-19; GWAS; Host genetic factors; Mortality; SARS-CoV-2; UK Biobank
Authors: Matt Arentz; Eric Yim; Lindy Klaff; Sharukh Lokhandwala; Francis X Riedo; Maria Chong; Melissa Lee Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Pankaj B Agrawal; Christopher R Pierson; Mugdha Joshi; Xiaoli Liu; Gianina Ravenscroft; Behzad Moghadaszadeh; Tiffany Talabere; Marissa Viola; Lindsay C Swanson; Göknur Haliloğlu; Beril Talim; Kyle S Yau; Richard J N Allcock; Nigel G Laing; Mark A Perrella; Alan H Beggs Journal: Am J Hum Genet Date: 2014-07-31 Impact factor: 11.025
Authors: Qiuyu Zhu; Munekazu Yamakuchi; Sara Ture; Maria de la Luz Garcia-Hernandez; Kyung Ae Ko; Kristina L Modjeski; Michael B LoMonaco; Andrew D Johnson; Christopher J O'Donnell; Yoshimi Takai; Craig N Morrell; Charles J Lowenstein Journal: J Clin Invest Date: 2014-09-17 Impact factor: 14.808
Authors: Cathie Sudlow; John Gallacher; Naomi Allen; Valerie Beral; Paul Burton; John Danesh; Paul Downey; Paul Elliott; Jane Green; Martin Landray; Bette Liu; Paul Matthews; Giok Ong; Jill Pell; Alan Silman; Alan Young; Tim Sprosen; Tim Peakman; Rory Collins Journal: PLoS Med Date: 2015-03-31 Impact factor: 11.069
Authors: Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971
Authors: Fanny Pojero; Giuseppina Candore; Calogero Caruso; Danilo Di Bona; David A Groneberg; Mattia E Ligotti; Giulia Accardi; Anna Aiello Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923